ArticleACS omega2026
3D-Printed Vancomycin-Loaded ZIF-8@GMP Scaffolds with Sustained Antibacterial, Anti-Inflammatory, and Osteoinductive Properties for Bone Tissue Engineering.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gelatin-based hydrogels have garnered significant attention in bone tissue engineering due to their excellent biocompatibility and ease of processing. However, their inherent limitations, such as poor mechanical strength and weak anti-inflammatory and antibacterial properties, restrict their broader application. To overcome these challenges, we developed a multifunctional 3D-printed scaffold by in situ growth of zeolitic imidazolate framework-8 (ZIF-8) nanoparticles within a creatine phosphate and methacrylic anhydride-modified gelatin matrix (GMP, methacrylation degree: 52.00%, creatine phosphate grafting rate: 17.89%), followed by vancomycin (VAN) loading. The resulting VAN/ZIF-8@GMP scaffolds exhibited prominent sustained drug release (78.89% VAN released at 96 h, vs 94.42% for direct blending scaffolds), enhanced antibacterial activity with 100% inhibition rate against both
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.